The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of orienX010 in stage IV melanoma with liver metastases.
 
Chuanliang Cui
No Relationships to Disclose
 
Bin Lian
Honoraria - Merck Sharp & Dohme; Novartis
 
Yue Yang
No Relationships to Disclose
 
Shanshan Yin
No Relationships to Disclose
 
Yue Cong
No Relationships to Disclose
 
Xuan Wang
Consulting or Advisory Role - Oriengene
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche China; Shanghai Junshi Biosciences
 
Zhihong Chi
No Relationships to Disclose
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Yan Kong
No Relationships to Disclose
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
Research Funding - MSD
 
Li Zhou
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Xue Bai
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Caili Li
No Relationships to Disclose
 
Xiaoting Wei
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; Merck Sharp & Dohme; Novartis; Roche; Shanghai Junshi BioSciences; Simcere